Background
Phase III, double-blind, placebo-controlled RCT (JAVELIN Head and Neck 100) of 697 patients with locally advanced, high-risk squamous-cell carcinoma of the head and neck, testing addition of avelumab to definitive chemoradiation followed by avelumab maintenance.
Interventions and follow up
Arm A: avelumab 10 mg/kg lead-in (7 days prior) then avelumab 10 mg/kg IV q2wk plus CRT*, followed by avelumab 10 mg/kg q2wk maintenance for 12 months
Arm B: placebo plus CRT*, followed by placebo maintenance
Primary endpoint: progression-free survival
mFollow up: 14.6 months
*CRT: cisplatin 100 mg/m2 q3wk plus IMRT 70 Gy in 35 fractions over 7 weeks
Arm B: placebo plus CRT*, followed by placebo maintenance
Primary endpoint: progression-free survival
mFollow up: 14.6 months
*CRT: cisplatin 100 mg/m2 q3wk plus IMRT 70 Gy in 35 fractions over 7 weeks
Results
mPFS: not reached in either arm; HR 1.21, 95% CI 0.93-1.57; P=.92 (numerically favoring placebo)
Outcome: trial stopped early at planned interim analysis for futility
OS: no benefit observed
Outcome: trial stopped early at planned interim analysis for futility
OS: no benefit observed
Adverse events
Grade ≥3 (arm A vs B): neutropenia 16% vs 15%; mucosal inflammation 14% vs 13%; dysphagia 14% vs 14%; anemia 12% vs 13%
Serious treatment-related AEs (arm A vs B): 36% vs 32%; treatment-related deaths 2 patients vs 1 patient
Serious treatment-related AEs (arm A vs B): 36% vs 32%; treatment-related deaths 2 patients vs 1 patient
Conclusions
Adding avelumab to standard cisplatin-based chemoradiation, with maintenance, did not improve progression-free survival in locally advanced HNSCC; the trial was terminated early for futility. Concurrent chemoradiation alone remains standard for this population.
Key Limitations
Negative trial; concurrent (rather than sequential/maintenance-only) immunotherapy with chemoradiation may have been suboptimal; possible negative interaction between PD-L1 blockade and concurrent cisplatin/RT lymphodepletion. Findings may not generalize to other anti-PD-1/L1 agents or scheduling strategies.
Clinical Context
JAVELIN Head and Neck 100 is a landmark negative trial; avelumab gained no approval in this setting. ESMO guidelines maintain concurrent cisplatin-based chemoradiation as standard definitive therapy for locally advanced HNSCC, with no established role for adding immune checkpoint inhibitors to CRT outside clinical trials.